Dublin, Oct. 24, 2022 (GLOBE NEWSWIRE) -- The "2022 Microbiome Market Trend" report has been added to ResearchAndMarkets.com's offering.
Advances in research have shown that many diseases and health conditions relate to alterations in the microbiome. As a result, research for diagnosis, analysis, testing, and development of therapeutic drugs, health foods, and livestock industry applications has increased.
The spread of COVID-19 caused delays in clinical trials and investment activities, increasing the risk to the sustainability of development. However, as the COVID-19 issue has raised public health concerns, some companies have positioned their strategies as development to combat COVID-19 infections and have initiated clinical trials intending to introduce products that enable a robust immune response.
The microbiome therapeutics market has advanced to Phase 3 with Seres Therapeutics' "SER-109" and Rebiotix' "RBX-2660" for Recurrent C. difficile. In addition to the therapeutics market, the microbiome is used in food-related, skincare, and industrial applications.
Key Topics Covered:
Chapter 1. Microbiome Market Trends
1.1 Microbiome Market Summary
1.2 Emerging integrators
1.3 Major Probiotic Companies
1.4 Examples of industrial chains
1.5 Postbiotics
1.6 Regulation
1.7 Technology platform overview
1.8 Fecal microbial transplantation (FMT)
1.9 Encapsulation technology
Chapter 2. Analysis by microbiome application
2.1 Therapeutics
2.2 Diagnosis
2.3 Functional food
2.4 Skin Care
2.5 Agriculture, Livestock and Fisheries
2.6 Industrial and other
Chapter 3. Trend Analysis by Company
Chapter 4. Market Size Forecast
Chapter 5. Trend Analysis by Country
Chapter 6. Conclusion
6.1. Competitive Environment Analysis
6.2 Conclusion
Companies Mentioned
- BGI
- Chr. Hansen
- DuPont
- Enterome
- Evelo Biosciences
- Gallinee
- Ginkgo Bioworks
- Illumina
- L'Oreal
- Morinaga
- Nestle
- Probi
- Rebiotix
- Seres Therapeutics
- Vedanta Biosciences
- Yakult Honsha
For more information about this report visit https://www.researchandmarkets.com/r/jfdzp2
Attachment
